EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

ADT increases prostate cancer cell invasion via altering AR/SALL4/SOX2-OCT4 stem cell signaling

Changcheng Guo, Aimaitiaji Kadier, Zhijin Zhang, Shiyu Mao, Bin Yang, Junhua Zheng, Xudong Yao

Cell Biology and Toxicology · 19.06.2025 · 41 (1)

DOI: 10.1007/s10565-025-10046-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Biology and Toxicology, online erschienen am 19.06.2025. Verfasst von Changcheng Guo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China. Hauptthemen laut MEDLINE: Octamer Transcription Factor-3, Prostatic Neoplasms, Receptors, Androgen, Neoplastic Stem Cells. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Early studies indicated that the androgen-deprivation-therapy with antiandrogen Enzalutamide (Enz) could increase prostate cancer patients' survival by an average of 4.8 months. Yet Enz might also have some adverse effects via increasing the prostate cancer (PCa) cell invasion. Here we found Enz treatment could increase SALL4 expression to increase the cancer stem cells-like (CSC-like) population that resulted in increasing the PCa cell invasion. Mechanism dissection revealed that Enz could function via androgen receptor (AR) to transcriptionally regulate the SALL4 expression via direct binding on the SALL4 5'-promoter. The consequences of such Enz/AR/SALL4 axis could upregulate the SOX2-OCT4 expression to increase the CSC-like population and the PCa cells invasion. Together, results from multiple in vitro and in vivo experiments all conclude that Enz may induce the adverse effect of increasing PCa cells invasion via altering the AR/SALL4/SOX2-OCT4 signaling to increase the CSC-like population, and targeting SALL4 may decrease this adverse effect for further suppress the PCa progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Octamer Transcription Factor-3Prostatic NeoplasmsReceptors, AndrogenNeoplastic Stem CellsAndrogen AntagonistsTranscription FactorsMaleHumansSOXB1 Transcription FactorsSignal TransductionBenzamidesPhenylthiohydantoinCell Line, TumorAnimalsNeoplasm InvasivenessNitrilesMiceGene Expression Regulation, NeoplasticMice, Nude

Stichwörter der Autor:innen

Cancer stem cells-likeDrug resistanceProstate cancerSALL4

Substanzen

SOXB1 Transcription FactorsOctamer Transcription Factor-3Receptors, AndrogenSOX2 protein, humanPOU5F1 protein, humanenzalutamideBenzamidesAndrogen AntagonistsTranscription FactorsPhenylthiohydantoin

Autor:innen und Institutionen

  • Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
  • Department of Urology, Renji Hospital, School of Medicine in Shanghai Jiao Tong University, Shanghai, 200072, China.
  • Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China. yaoxudong1967@163.com.

Zitieren

APA

Guo, C., Kadier, A., Zhang, Z., Mao, S., Yang, B., Zheng, J., & Yao, X. (2025). ADT increases prostate cancer cell invasion via altering AR/SALL4/SOX2-OCT4 stem cell signaling. Cell Biology and Toxicology, 41(1). https://doi.org/10.1007/s10565-025-10046-2

Vancouver

Guo C, Kadier A, Zhang Z, Mao S, Yang B, Zheng J, et al. ADT increases prostate cancer cell invasion via altering AR/SALL4/SOX2-OCT4 stem cell signaling. Cell Biology and Toxicology. 2025;41(1). doi:10.1007/s10565-025-10046-2

BibTeX
@article{Guo2025,
  author = {Guo, Changcheng and Kadier, Aimaitiaji and Zhang, Zhijin and Mao, Shiyu and Yang, Bin and Zheng, Junhua and Yao, Xudong},
  title = {ADT increases prostate cancer cell invasion via altering AR/SALL4/SOX2-OCT4 stem cell signaling},
  journal = {Cell Biology and Toxicology},
  year = {2025},
  volume = {41},
  number = {1},
  doi = {10.1007/s10565-025-10046-2}
}
Kostenlos starten →